Figure 7.

Anti-colitis Effect of Engineered MSC Depends on CX3CR1 and IL-25 Function

CX3CR1&IL-25-LV-MSCs pre-incubated with CX3CR1 antibody (10 μg/mL) or mouse IgG were administered into mice with DSS colitis by tail vein injection on days 4, 6, and 8. Mice were treated with dual-functionalized MSCs (intravenous injection) and IL-25 antibody (intraperitoneal injection) on days 4, 6, and 8. (A and B) Survival analysis was performed (A), and body weight was measured daily to monitor colitis severity (B). (C) Colons excised from mice with DSS-induced colitis were photographed. (D and E) The DAI was determined (D), and the colon length was measured (E). (F) Colonic MPO activity was examined. (G and H) Colon sections from mice that had undergone different treatments were examined by H&E staining (G), and histopathological scoring was analyzed (H). Scale bars, 100 μm. Values are expressed as the mean ± SEM (n = 7 mice per group). *p < 0.05; **p < 0.01.